Isaac Ssewanyana
ID: UNCST-2020-R014336
|
Protocol for the establishment of clinical specimen panel for WHO Prequalification performance evaluation of HIV serology assays
REFNo: HS2786ES
To establish an HIV specimen repository at ITM.,To register the specimens into a Biobank at ITM; ,To characterize the specimens for HIV and syphilis serostatus using standardized reference assays and algorithms at ITM;,To collect biological specimens from patients with known HIV serostatus or blood donors from different regions of the world to establish a WHO HIV specimen evaluation panel that will be used for the laboratory performance evaluation of HIV serology assays undergoing WHO prequalification assessment; ,The overall objective is to assemble a new WHO HIV specimen evaluation panel in collaboration with PELs and collaborating centers, which will be made accessible on demand to all the PELs conducting HIV or dual HIV-syphilis serology test evaluations for WHO prequalification.,
|
Uganda |
2023-04-12 12:56:08 |
2026-04-12 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Edgar Mulogo Mugema
ID: UNCST-2023-R008170
|
Environmental Drivers of Pediatric Postinfectious Hydrocephalus in Western Uganda: Case-Control Study
REFNo: HS2699ES
The overarching objective of the study is to elucidate potential factors that underlie the ecological correlation between precipitation and PIH. Identification of these environmental intermediaries may elucidate potential targets for intervention to reduce the incidence of PIH.,
|
Uganda |
2023-04-11 15:42:30 |
2026-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
A multiple arm, multiple stage (MAMS), phase 2B/C, open label, randomized, controlled platform trial to evaluate experimental arms including an increased dose of rifampicin, an optimized dose of pyrazinamide, moxifloxacin and sutezolid, in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis
REFNo: HS2644ES
Primary Efficacy Objective:
Rifampicin- containing experimental arms (arms 1,2)
To evaluate whether one or more of two experimental regimens based on
optimized dose rifampicin, optimized dose of pyrazinamide, and moxifloxacin
given for 12, respectively 17 weeks, are superior to standard treatment given for
26 weeks, as assessed by time to sputum culture conversion to negative in liquid
media.
Sutezolid-containing experimental arm (arm 4)
To evaluate whether the efficacy of an experimental regimen composed of
sutezolid, delamanid, bedaquiline, and moxifloxacin given for 17 weeks is
superior to standard treatment given for 26 weeks, as assessed by time to
sputum culture conversion to negative in liquid media.
Secondary Objectives This study’s secondary objectives are:
Efficacy
To assess treatment efficacy based on proportion of patients with relapse
free outcome at 12 months after randomization.
To assess treatment efficacy based on the rate of decline of bacterial load
measured by the Molecular Bacterial Load Assay
To rank the relative efficacy of the experimental four-drug combinations
for the treatment of pulmonary tuberculosis within the first twelve weeks
of treatment, and select the most efficient experimental treatment
regimen or regimens for further development.
Safety and Tolerability
To assess the frequency, severity, and type of adverse events (AEs), and AErelated
treatment discontinuations.
Pharmacokinetics
To describe the pharmacokinetics of the drugs and doses used, and to assess
possible relationships between pharmacokinetic parameters of the various drugs and between pharmacokinetic parameters and participant characteristics.
Pharmacodynamics To describe relationships between pharmacokinetic parameters on the one hand and efficacy and safety endpoints on the other hand.
|
Uganda |
2023-04-11 15:27:11 |
2026-04-11 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Andrew Muhumuza
ID: UNCST-2022-R009010
|
Incidence and predictors of castration resistance among patients with prostate cancer on androgen deprivation therapy at two referral hospitals in Uganda
REFNo: HS2759ES
To identify the predictors of castration resistance among prostate cancer patients on ADT at Mbarara Referral Hospital oncology unit and Uganda cancer Institute, Mulago National Referral Hospital. ,To determine the incidence of castration resistance among patients with prostate cancer on ADT at Mbarara Referral Hospital oncology unit and Uganda cancer Institute, Mulago National Referral Hospital.,To determine the incidence and predictors of castration resistance among prostate cancer patients on ADT at Mbarara Referral Hospital oncology unit and Uganda cancer Institute, Mulago National Referral Hospital.,
|
Uganda |
2023-04-11 14:20:29 |
2026-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
SAM ALI
ID: UNCST-2020-R014824
|
Stillbirth in High Burden Settings: Ample Room for Improvement using Biomarkers and Ultrasound Technologies (iTECH)
REFNo: HS2762ES
1. To evaluate the relation between placental histopathological lesions and biomarkers, placenta ultrasound and hemodynamic changes after stillbirth and near miss stillbirth in order to understand the underlying mechanisms and specify the prediction model.
2. To engage with important stakeholders on the value of these diagnostic technologies in the community, co-creating the project design, implementation and eventual uptake into practice guidelines.
3. To establish the predictive performance of maternal characteristics and markers emerging from this project for stillbirth and other related endpoints in non-anomalous fetuses and assess the feasibility of integrating relevant markers into clinical decision support tools.
4. To prospectively evaluate patterns of (bio)markers, maternal cardiovascular function and contemporary ultrasound markers in pregnancy, to understand their role in the chain of events and pathophysiology of stillbirth in a resource poor setting.
5. To develop and validate a prediction model for use at the point of care in low-and middle-incomes countries (LMICs) to quantify a woman’s individual risk of antepartum stillbirth based on a set of easily measurable, accessible, highly predictive and cost-effective markers, and make it freely available for healthcare providers in low-resource settings.
|
Uganda |
2023-04-06 8:06:27 |
2026-04-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|